WESTON, MA – The U.S. Food and Drug Administration has approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
“No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients,” said Russell Katz, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Multiple sclerosis can impair movement, sensation and thinking and have a profound impact on a person’s quality of life.”
Results from two clinical trials showed that those taking Tecfidera had fewer MS relapses compared with people taking an inactive pill (placebo). Tecfidera is made by Biogen Idec, Weston, MA.
While veterans serving in the military during the Gulf War era (GWE) appear to have higher risk for multiple sclerosis and a range of neurological illnesses, little has been documented previously on prevalent types of MS or other clinical features.
With a long history of point of care testing at both of its predecessor organizations, the Walter Reed National Military Medical Center (WRNMMC) laboratory services staff were keenly aware of the advantages of using portable testing devices to obtain rapid patient assessments.